$42.79
1.03% today
Nasdaq, Aug 22, 04:48 pm CET
ISIN
US4622221004
Symbol
IONS

Ionis Pharmaceuticals, Inc. Stock price

$43.24
+1.69 4.06% 1M
+10.92 33.77% 6M
+8.28 23.67% YTD
-4.95 10.26% 1Y
-0.79 1.78% 3Y
-9.44 17.91% 5Y
-3.43 7.34% 10Y
+38.19 756.14% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+0.43 0.99%
ISIN
US4622221004
Symbol
IONS
Industry

Key metrics

Basic
Market capitalization
$6.9b
Enterprise Value
$5.9b
Net debt
positive
Cash
$2.3b
Shares outstanding
159.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.3 | 8.9
EV/Sales
6.2 | 7.6
EV/FCF
negative
P/B
10.9
Financial Health
Equity Ratio
19.6%
Return on Equity
-77.2%
ROCE
-12.8%
ROIC
-45.4%
Debt/Equity
2.0
Financials (TTM | estimate)
Revenue
$944.1m | $770.1m
EBITDA
$-244.9m | $-398.4m
EBIT
$-266.5m | $-428.6m
Net Income
$-268.2m | $-500.9m
Free Cash Flow
$-290.0m
Growth (TTM | estimate)
Revenue
16.1% | 9.2%
EBITDA
29.9% | 12.1%
EBIT
27.4% | 9.8%
Net Income
26.7% | -10.4%
Free Cash Flow
19.0%
Margin (TTM | estimate)
Gross
98.9%
EBITDA
-25.9% | -51.7%
EBIT
-28.2%
Net
-28.4% | -65.0%
Free Cash Flow
-30.7%
More
EPS
$-1.5
FCF per Share
$-1.8
Short interest
9.6%
Employees
1k
Rev per Employee
$660.0k
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

24x Buy
73%
8x Hold
24%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
24%
Sell
3%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
944 944
16% 16%
100%
- Direct Costs 11 11
9% 9%
1%
934 934
16% 16%
99%
- Selling and Administrative Expenses 317 317
23% 23%
34%
- Research and Development Expense 883 883
3% 3%
94%
-245 -245
30% 30%
-26%
- Depreciation and Amortization 22 22
22% 22%
2%
EBIT (Operating Income) EBIT -267 -267
27% 27%
-28%
Net Profit -268 -268
27% 27%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Positive
Reuters
about 24 hours ago
The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder.
Neutral
Business Wire
about 24 hours ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. DAWNZERA is the first and only RNA-targeted medicine approved for HAE, designed to target p...
Positive
The Motley Fool
22 days ago
Ionis Pharmaceuticals (IONS -0.44%), a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat on both GAAP revenue and non-GAAP earnings compared to Wall Street estimates.
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 1,069
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today